**Grants Awarded through Expression of Interest Process**

**1 January 2018 to 31 December 2018**

|  |  |
| --- | --- |
| **Antiviral Strategies** | |
| Dr. Cody **Allison** | Investigating the efficacy of tenofovir alafenamide in preventing HTLV-1 transmission in a humanised mouse model of infection |
| Dr. Jenny **Anderson** | Putting the Kill in “Shock and Kill” to Eliminate Latent HIV |
| Dr. Simon **Cook** | Tough hydrogel materials as drug delivery vehicles for prevention and treatment of HIV and other sexually transmitted infections |
| Professor Tony **Cunningham** | Development of gene therapy to prevent HIV inhibition of interferon production in human macrophages and dendritic cells |
| Dr. Karla **Helbig** | Targeting CK2 to enhance treatment strategies for HBV |
| Hongping **Jin** | Nanomedicine for HIV therapy |
| Dr. Julie **Nigro** | Developing 3-dimensional hepatitis B-liver organoids to screen future antiviral therapeutic |
| Professor Gilda **Tachedjian** | Targeting cervicovaginal inflammation to prevent HIV transmission’ |
| **Diagnostics / Prognostics** | |
| A/Professor Melissa **Churchill** | Developing BASEScope: a method to detect replication competent HIV for HIV cure research |
| Dr. Lloyd **Einsiedel** | Developing prognostic markers for HTLV-1 associated inflammatory disease in central Australia |
| Dr. Margaret **Littlejohn** | A new assay and cell culture system to progress pan-genotypic HBV cure research |
| A/Professor Sarah **Palmer** | Defining Persistent Reservoirs of HIV-1 after Vacc-4x and Romidepsin Therapy |
| Professor Nicolas **Shackel** | Transcription of integrated HBV DNA as a marker of chronic HBV treatment outcome |
| Professor Kumar **Visvanathan** | Immunovirological determinants and consequences of ALT flares in chronic HBV patients |
| **Vaccine Targets** | |
| Heidy E **Drummer** | Optimization of HCV vaccine formulations for clinical trials |
| Dr. Gregor **Ebert** | Examination of reduced hepatitis B virus vaccine efficacy in Indigenous Australians and its implications for vaccination strategy, policy and practice |
| Dr. Eric **Gowans** | HCV challenge studies in vaccinated mice |
| Professor Johnson **Mak** | Evaluating pre-entry primed HIV particles as a vaccine candidate |
| Dr. P **Poumbourious** | Immunogenicity screening and downselection of novel epitope enhanced HIVS1 glycoprotein vaccines for studies in non-human primates |